Hydroxychloroquine: Serious skin adverse events ‘rare’
Fewer than 4% of events reported to the FDA were for Stevens-Johnson syndrome or toxic epidermal necrolysis
The antimalarial hydroxychloroquine can be associated with serious dermatological adverse events, but they are rare, new findings show.
US researchers retrospectively reviewed 1970-2019 data from the US Food and Drug Administration Adverse Event Reporting System (FAERS) on adverse reactions linked to hydroxychloroquine, analysing 9242 cases.
